DDInter596 DDInter1731
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Doxorubicin {u} (Compound) treats {v} (Disease) pancreatic cancer
pancreatic cancer {u} (Disease) is treated by {v} (Compound) Sunitinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) STK10
STK10 {u} (Gene) is bound by {v} (Compound) Sunitinib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sunitinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) PLK4
PLK4 {u} (Gene) is bound by {v} (Compound) Sunitinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) PCK2
PCK2 {u} (Gene) is upregulated by {v} (Compound) Sunitinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Sunitinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) MCM10
MCM10 {u} (Gene) is downregulated by {v} (Compound) Sunitinib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Candida infection
Candida infection {u} (Side Effect) is caused by {v} (Compound) Sunitinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) CHEK2
CHEK2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Sunitinib
Doxorubicin (Compound) treats pancreatic cancer (Disease) and pancreatic cancer (Disease) is treated by Sunitinib (Compound)
Doxorubicin (Compound) upregulates STK10 (Gene) and STK10 (Gene) is bound by Sunitinib (Compound)
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Doxorubicin (Compound) downregulates PLK4 (Gene) and PLK4 (Gene) is bound by Sunitinib (Compound)
Doxorubicin (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Sunitinib (Compound)
Doxorubicin (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Sunitinib (Compound)
Doxorubicin (Compound) downregulates MCM10 (Gene) and MCM10 (Gene) is downregulated by Sunitinib (Compound)
Doxorubicin (Compound) causes Candida infection (Side Effect) and Candida infection (Side Effect) is caused by Sunitinib (Compound)
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Doxorubicin (Compound) downregulates CHEK2 (Gene) and CHEK2 (Gene) is bound by Sunitinib (Compound) and CHEK2 (Gene) is downregulated by Sunitinib (Compound)